Insulin resistance: what it is and what actually improves it

Insulin is the hormone your pancreas releases after eating to tell muscle, fat, and liver cells to take up glucose from the bloodstream and either use it or store it. Insulin resistance is what happens when those cells stop responding normally to a given amount of insulin: they take up less glucose than they should, so the pancreas compensates by producing more insulin to hold blood glucose in the normal range.

That compensation can work for years, sometimes without any change in a standard fasting glucose reading, which is part of why insulin resistance is easy to miss early on. It is a slow-building physiological state, not a single event, and it is the process that eventually gives way to prediabetes and then type 2 diabetes once the pancreas can no longer keep up with the demand for extra insulin.

You cannot walk into a lab and get an “insulin resistance” reading the way you can get a cholesterol panel. What you get instead are indicators: fasting glucose, HbA1c (a measure of average blood glucose over roughly the prior two to three months), and calculated scores such as HOMA-IR, which estimates insulin resistance from a fasting glucose and fasting insulin value using a formula.^[3]

In the paper that introduced it, HOMA-IR correlated reasonably well with insulin resistance measured by the euglycemic clamp technique, the labor-intensive research method considered the gold standard (a correlation coefficient of 0.88), which is why it became the standard low-cost estimate used in research and, increasingly, in clinical practice.^[3]

A single HOMA-IR value is still only a moderately precise picture for an individual, not a diagnosis on its own. The distinction matters for how you should read any of these numbers: fasting glucose, HbA1c, and HOMA-IR are useful for flagging risk and tracking change over time, but a clinician interprets them together with your history and other risk factors, not as a stand-alone verdict.

Insulin resistance is not just a laboratory curiosity. It is considered a central physiological driver behind most cases of prediabetes and type 2 diabetes, and it clusters with the other features of metabolic syndrome: central (visceral) fat, elevated blood pressure, and an unfavorable lipid profile. The Diabetes Prevention Program, the trial at the center of this article, specifically enrolled adults with impaired glucose tolerance and elevated fasting glucose, a prediabetic, insulin-resistant state that carries a substantially elevated risk of progressing to full type 2 diabetes.^[1]

That is also why insulin resistance belongs alongside GLP-1 medications for weight loss in this hub: both topics sit at the intersection of body weight and glucose metabolism, even though the evidence base and the tools involved are quite different.

The Diabetes Prevention Program (DPP) is the trial most directly relevant to the question of what actually reduces the real-world consequence of insulin resistance: progressing to diabetes. It randomized more than 3,000 adults with impaired glucose tolerance and elevated fasting glucose to one of three groups (an intensive lifestyle intervention, metformin, or placebo) and followed them for an average of about three years.^[1] The lifestyle intervention had two explicit, measurable goals: losing at least 7% of body weight and doing at least 150 minutes of moderate physical activity per week, supported by individual counseling on diet and behavior change.^[1]

The results were unambiguous. Compared with placebo, the intensive lifestyle intervention reduced the incidence of type 2 diabetes by 58% (95% confidence interval, 48 to 66 percent), and metformin reduced it by 31% (95% confidence interval, 17 to 43 percent).^[1]Lifestyle change was significantly more effective than the drug, not just numerically larger. Put another way, the trial’s own numbers showed that 6.9 people needed to complete the lifestyle program to prevent one case of diabetes over three years, compared with 13.9 people for metformin.^[1]

A common, fair objection to prevention trials is that short-term results do not always hold up. The DPP Outcomes Study followed the original participants for a decade after randomization to see whether the advantage held.^[2] It is worth being precise about the design here: after the initial trial phase ended, participants in the original placebo group were also offered lifestyle intervention support, so the 10-year comparison is a longer-term observational follow-up of the original trial groups, not a continued three-way blinded drug trial.^[2]

Even with that caveat, the result is notable: diabetes incidence over the full 10 years was still 34% lower in the original lifestyle group and 18% lower in the original metformin group, compared with the original placebo group.^[2]Prevention or delay achieved in the first three years did not simply wash out once the trial’s original intensive support ended.

It is worth pausing on how unusual the DPP’s headline comparison is: a lifestyle intervention beat a real, still-prescribed diabetes medication at its own job, not narrowly, but by a wide margin (58% versus 31% risk reduction).^[1]Metformin’s main actions are reducing glucose production by the liver and modestly improving insulin sensitivity. The lifestyle intervention worked through more channels at once: losing visceral fat, increasing muscle glucose uptake through regular activity, and improving diet quality, alongside behavioral support to sustain the changes.

This context also explains why lifestyle change and metformin are not usually framed as competing options in clinical practice. Metformin is sometimes added for people at particularly high risk of progressing, or who cannot sustain the intensity of lifestyle change the DPP protocol used, but the trial’s own results are the strongest argument for making weight loss and physical activity the first target rather than an afterthought.

The DPP tested a specific, bundled intervention (weight loss plus activity, with counseling), not each ingredient in isolation, so it cannot tell us precisely how much of the benefit came from diet quality versus exercise versus the fat lost specifically from around the organs (visceral fat) versus the coaching itself. Evidence outside the DPP is more preliminary but points in a consistent direction.

Diet quality (more whole foods and fiber, less ultra-processed food and free sugar) and loss of visceral fat specifically, rather than weight loss anywhere on the body, both track with improved insulin sensitivity in observational and smaller trial data. Poor sleep and chronically elevated stress hormones are similarly associated with worse insulin sensitivity, plausibly by raising cortisol and disrupting the hormones that regulate appetite and glucose. None of these individual factors has been isolated and tested with anything close to the DPP’s scale or rigor, which is why they are best understood as reinforcing the same direction as the primary evidence, rather than independently proven interventions of their own.

For people whose insulin resistance has already progressed toward diabetes or obesity, and who do not achieve enough change through lifestyle intervention alone, medication is a separate, legitimate path. Our article on GLP-1 medications for weight loss covers the trial evidence for that drug class in detail. Lifestyle change and medication are not mutually exclusive, and the decision belongs with a treating clinician.

Search for insulin resistance online and you will find no shortage of supplements marketed as “insulin support,” “blood sugar balance,” or similar: berberine, chromium picolinate, cinnamon extract, alpha-lipoic acid, and inositol are among the most commonly sold. Some have biological plausibility and small human trials behind them.

None of them has been tested in a trial approaching the size, duration, or rigor of the DPP, and none has been shown, at the scale of a major outcome trial, to reduce the risk of progressing to type 2 diabetes. Small trials in this space are frequently short, inconsistently designed, and prone to the kind of mixed results that make strong marketing claims premature. Treat “clinically proven” language on supplement packaging with real skepticism, and mention any supplement you are taking or considering to your prescribing clinician, since some (herbal ingredients especially) can interact with diabetes medications.

Insulin resistance itself often has no symptoms, which is exactly why it can progress for years before a fasting glucose or HbA1c test flags it. Routine screening, not waiting for symptoms, is how most cases of prediabetes are actually found.

None of these symptoms is specific to insulin resistance on its own, but together they are the classic presentation of diabetes, and they warrant prompt testing rather than a wait-and-see approach.

Insulin resistance is a physiological state, not a single test result, and it sits upstream of prediabetes, type 2 diabetes, and metabolic syndrome. The best evidence for actually improving it, and for preventing the diabetes it leads to, comes from the Diabetes Prevention Program: an intensive, specific lifestyle intervention (at least 7% weight loss, at least 150 minutes of weekly activity) cut the incidence of type 2 diabetes by 58% compared with placebo, beat metformin’s 31% reduction, and the advantage was still measurable a decade later. Diet quality, visceral fat loss, sleep, and stress management plausibly reinforce that same direction, while marketed insulin-support supplements remain, at best, unproven at that scale. See how we grade the strength of evidence across topics in our editorial and evidence standards, and browse the rest of our Weight & Metabolic Health coverage as it grows.

None of this replaces individual clinical testing and diagnosis. It reflects what the pivotal trials actually show: a genuinely effective, evidence-backed program for reducing diabetes risk, not a single number to chase or a supplement to buy.